Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Frank Kolbinger, PhD Executive Director at Novartis Pharma AG


Frank Kolbinger, Ph.D. is currently Research Representative for the  anti-IL17A monoclonal antibody secukinumab (Cosentyx, AIN457) approved for Psoriasis, Psoriatic Arthritis and Ankylosing spondylitis and the anti-IL-17A antibody CJM112 at proof of concept stage in Hidradenitis suppurativa. Frank joint the Cosentyx team about 6 years ago and contributed to the regulatory filling and approval as well as the elucidation of the mode of action of Cosentyx in Psoriasis.

Frank joined Ciba-Geigy, one of the predecessor companies of Novartis in March 1994 as Laboratory Head in the Central Research Labs. After the foundation of Novartis, he held various positions with increasing responsibility in the Transplantation Therapeutic Area (Scientific Expert in Molecular and Cellular Biology), Discovery technologies (Group Leader Protein Production) and Novartis Biologics (Head of Antibody Center) before he joined the Autoimmunity, Transplantation & Inflammation (ATI) therapeutic area in 2008 as a Biologics Expert. In his current role in the ATI Translational Research Group he focuses on translational research and scientific support of advanced and late stage therapeutic projects.

Agenda Sessions